A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab or Conatumumab in Combination With FOLFIRI for Second-Line Treatment of Mutant KRAS Metastatic Colorectal Cancer / Cohn, Al; Tabernero, J; Maurel, J; Nowara, E; Sastre, J; Chuah, Bys; Kopp, Mv; Sakaeva, Dd; Mitchell, Ep; Dubey, S; Suzuki, S; Hei, Y; Galimi, Francesco; Mccaffery, I; Pan, Y; Loberg, R; Cottrell, S; Choo, Sp. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 24:7(2013), pp. 1777-1785. [10.1093/annonc/mdt057]

A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab or Conatumumab in Combination With FOLFIRI for Second-Line Treatment of Mutant KRAS Metastatic Colorectal Cancer

GALIMI, Francesco;
2013

A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab or Conatumumab in Combination With FOLFIRI for Second-Line Treatment of Mutant KRAS Metastatic Colorectal Cancer / Cohn, Al; Tabernero, J; Maurel, J; Nowara, E; Sastre, J; Chuah, Bys; Kopp, Mv; Sakaeva, Dd; Mitchell, Ep; Dubey, S; Suzuki, S; Hei, Y; Galimi, Francesco; Mccaffery, I; Pan, Y; Loberg, R; Cottrell, S; Choo, Sp. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 24:7(2013), pp. 1777-1785. [10.1093/annonc/mdt057]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/47795
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 75
  • ???jsp.display-item.citation.isi??? 72
social impact